ImmunityBio, Inc.

NasdaqGS:IBRX Stock Report

Market Cap: US$2.1b

ImmunityBio Management

Management criteria checks 2/4

ImmunityBio's CEO is Rich Adcock, appointed in Oct 2020, has a tenure of 5.17 years. total yearly compensation is $10.95M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $715.61K. The average tenure of the management team and the board of directors is 4.4 years and 5.3 years respectively.

Key information

Rich Adcock

Chief executive officer

US$11.0m

Total compensation

CEO salary percentage7.32%
CEO tenure5.2yrs
CEO ownership0.03%
Management average tenure4.4yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain

Dec 19

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 07
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 07

Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Mar 06
Earnings Update: ImmunityBio, Inc. (NASDAQ:IBRX) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

Dec 11

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

Oct 25

ImmunityBio: Moving The Needle

Oct 07

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 21

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 14

ImmunityBio: All Eyes On Execution Now (Rating Upgrade)

Jul 09

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

Jun 25

ImmunityBio: Anktiva's Launch Demands A Reassessment

Jun 06

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle

Apr 23

ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise

Feb 27

ImmunityBio: Buy Low Now Vs. Buy High Later

Feb 11

CEO Compensation Analysis

How has Rich Adcock's remuneration changed compared to ImmunityBio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$349m

Jun 30 2025n/an/a

-US$367m

Mar 31 2025n/an/a

-US$409m

Dec 31 2024US$11mUS$802k

-US$414m

Sep 30 2024n/an/a

-US$588m

Jun 30 2024n/an/a

-US$598m

Mar 31 2024n/an/a

-US$601m

Dec 31 2023US$1mUS$796k

-US$583m

Sep 30 2023n/an/a

-US$458m

Jun 30 2023n/an/a

-US$473m

Mar 31 2023n/an/a

-US$430m

Dec 31 2022US$4mUS$791k

-US$417m

Sep 30 2022n/an/a

-US$400m

Jun 30 2022n/an/a

-US$376m

Mar 31 2022n/an/a

-US$370m

Dec 31 2021US$29mUS$765k

-US$347m

Sep 30 2021n/an/a

-US$323m

Jun 30 2021n/an/a

-US$301m

Mar 31 2021n/an/a

-US$264m

Dec 31 2020US$843kUS$141k

-US$222m

Compensation vs Market: Rich's total compensation ($USD10.95M) is above average for companies of similar size in the US market ($USD5.44M).

Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.

CEO

Rich Adcock (56 yo)

5.2yrs
Tenure
US$10,954,875
Compensation

Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...

Leadership Team

NamePositionTenureCompensationOwnership
Patrick Soon-Shiong
Executive Chairman of the Board and Global Chief Scientific & Medical Officer11.1yrsUS$8.22m29.57%
$ 623.3m
Richard Adcock
President5.2yrsUS$10.95m0.034%
$ 715.6k
David Sachs
Chief Financial Officer6.4yrsUS$3.38m0.023%
$ 482.9k
Barry Simon
Chief Corporate Affairs Officer & Director4.8yrsno data0.33%
$ 6.9m
Regan Lauer
Chief Accounting Officer4.1yrsno data0.011%
$ 235.9k
Enrique Diloné
Chief Technology Officer2.9yrsno datano data
Sarah Singleton
Chief Communications Officer & Head of Patient Advocacy5.8yrsno datano data
Emily Arison
Senior Vice President of Human Resources4.4yrsno datano data
Leonard Sender
Chief Medical Officer of Liquid Tumors & Cell Therapyless than a yearno datano data
Sandeep Reddy
Chief Medical Officer5.3yrsno datano data
Hans Klingemann
Chief Science Officer of Cellularno datano datano data
Manju Saxena
Senior VP of Product Development & Cell Therapy Program1.9yrsno datano data
4.4yrs
Average Tenure
58yo
Average Age

Experienced Management: IBRX's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Patrick Soon-Shiong
Executive Chairman of the Board and Global Chief Scientific & Medical Officer11.1yrsUS$8.22m29.57%
$ 623.3m
Richard Adcock
President4.8yrsUS$10.95m0.034%
$ 715.6k
Barry Simon
Chief Corporate Affairs Officer & Director18.9yrsno data0.33%
$ 6.9m
Christobel Selecky
Independent Director5.3yrsUS$470.00k0%
$ 0
Wesley Clark
Independent Director4.8yrsUS$465.00k0.00081%
$ 17.1k
Bruce Wendel
Independent Directorno datano datano data
Michael Blaszyk
Independent Director10.4yrsUS$510.00k0.027%
$ 568.3k
Cheryl Cohen
Lead Independent Director6.5yrsUS$512.50k0.020%
$ 429.4k
Linda Maxwell
Independent Director4.8yrsUS$487.50k0%
$ 0
5.3yrs
Average Tenure
70yo
Average Age

Experienced Board: IBRX's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 13:01
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ImmunityBio, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin ZelinBTIG
Suranjit MukherjeeBTIG
Jason KolbertD. Boral Capital LLC.